- Merck (MRK +0.9%), through a subsidiary, extends its existing collaboration and license agreement with Agenus (AGEN +1.6%) for the discovery and development of therapeutic antibodies to Merck's proprietary immune checkpoints to April 2016.
- Under the terms of the original agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using its Retrocyte Display platform. Agenus is eligible to receive up to $100M in milestones and royalties on global commercial sales.